Halozyme Therapeutics Inc. (HALO) Next Earnings Date & Options-Implied ±6.5% Move

$131.18 +0.88% NASDAQ • Public Delayed / 60s Snapshot

Halozyme Therapeutics Inc. (HALO) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.

ROARABLE C+ • HOLD / WATCH Cap $14.89B
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510067
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C+ · Rk C+
Cash (18)Whales (10)SEC (16)Macro (11)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+4% Base Target
$161 Bull$136 Base$106 Bear
🔴 SUNDAY NIGHT PREP • 7:00 PM ET
WHALE OPTIONS TUG-OF-WAR:60% Call Buyers ($2.7M)
40% PutsMax Pain: $129.00
NEXT EST. REPORT: Dec 30, 2026 (~59 DAYS)

Options-Implied Post-Earnings ±6.5% Bell Curve

±$8.53 Expected Swing
$122.65 (-6.5%)Spot $131.18$139.71 (+6.5%)
TRADER CROWD SENTIMENT POLL

Will HALO Beat & Rip or Miss Next Quarter?

Trailing EPS: $2.79 • YoY Revenue Growth: 37.6%

55% Bullish Beat45% Bearish Miss

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$1.40B$316.9M$644.6M83.6%
FY 20242024-12-31$1.02B$444.1M$468.4M84.3%
FY 20232023-12-31$829.3M$281.6M$351.3M44%
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Guest Options & Prop-Trading Strategist

Whale Flow & Momentum Playbook: Trading HALO & AI Leaders Without Chasing Tops

  • ✓Exact institutional whale strikes & implied earnings range on HALO this week
  • ✓How active traders scale setups using funded prop-firm accounts instead of risking savings
  • ✓Free bonus: instant RQD Rating Flip alerts on all tracked momentum leaders
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
HALO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +105.64%▲ RESISTANCE BREAKOUT
2026-10-30O $132.7H $134.0L $130.3C $130.9VOL 1.40M
RES: $130.0SUP: $95.62SMA50: $113.7SMA200: $83.37
$139.0$118.2$97.47$76.70$55.93RES $130.0SUP $95.62$130.92026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
34.7%/yr Implied 5Y Growth

vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HALO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

HALO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is HALO's next earnings date?

Based on SEC filing cadence, Halozyme Therapeutics Inc. (HALO)'s next quarterly earnings window is estimated around Dec 30, 2026.

How much is HALO stock expected to move on earnings?

Options markets currently imply a ±6.5% post-earnings move for HALO, projecting a trading range between $122.65 and $139.71.